Clinical Trials market in India has shown significant growth symptoms in the recent past

Friday, May 7, 2010 Research News J E 4
Clinical trials Market in India Clinical research experienced over 84% growth during 2006-2008 and it has its own merit in regards to further prospect considering global clinical market is growing at 12%. Clinical research industry in India touched US$258 million in 2008 up from US$140 million in 2006. An estimate shows that clinical research in India is expected to be US$320 million by 2009. ( ) The cost of conducting clinical trials in India for instance is 20 to 60 per cent of the cost in developed countries. Not surprisingly about 20 to 30 per cent of the clinical development activity is now outsourced to developing countries such as India. Currently there are more than 150 CROs in India out of which 20 comply with ICH-GCP guidelines. The leading players in India include Clinigene International Vimta Labs Ltd and Lotus labs besides multinationals like Quintiles Spectral Pharmanet SIRO Clinpharm and Clintec etc. In view of the growth potential and India’s strength in pharmaceuticals to qualify for clinical trials has come out with an updated version of the Clinical trials report. The report has total 9 chapters and all chapters are covered in such a fashion that one can understand all aspects of clinical trails industry in India well. This report mostly captures secondary information collected from various reliable information sources covering market information company specific vital information issues and challenges growth drivers and future outlook. The report will be useful for research analysts in the clinical research space investors interested in clinical research based companies students for clinical research who want to pursue career in CROs and various pharma companies who want to understand Indian clinical research industry in India. To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Follow us on twitter:


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Keryx Biopharmaceuticals Initiates Phase 3 Registr...
Cellular Dynamics Partners with iPS Academia Japan...